Scientists use sound waves to levitate liquids, improve pharmaceuticals

September 13, 2012

It's not a magic trick and it's not sleight of hand - scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects.

Scientists at the U.S. Department of Energy's (DOE) Argonne National Laboratory have discovered a way to use sound waves to levitate individual droplets of solutions containing different pharmaceuticals. While the connection between levitation and drug development may not be immediately apparent, a special relationship emerges at the molecular level.

At the molecular level, pharmaceutical structures fall into one of two categories: amorphous or crystalline. Amorphous drugs typically are more efficiently taken up by the body than their crystalline cousins; this is because amorphous drugs are both more highly soluble and have a higher bioavailability, suggesting that a lower dose can produce the desired effect.

"One of the biggest challenges when it comes to drug development is in reducing the amount of the drug needed to attain the therapeutic benefit, whatever it is," said Argonne X-ray physicist Chris Benmore, who led the study.

"Most drugs on the market are crystalline - they don't get fully absorbed by the body and thus we aren't getting the most efficient use out of them," added Yash Vaishnav, Argonne Senior Manager for Intellectual Property Development and Commercialization.

Getting pharmaceuticals from solution into an amorphous state, however, is no easy task. If the solution evaporates while it is in contact with part of a vessel, it is far more likely to solidify in its crystalline form. "It's almost as if these substances want to find a way to become crystalline," Benmore said.

In order to avoid this problem, Benmore needed to find a way to evaporate a solution without it touching anything. Because liquids conform to the shape of their containers, this was a nearly impossible requirement -- so difficult, in fact, that Benmore had to turn to an acoustic levitator, a piece of equipment originally developed for NASA to simulate microgravity conditions.

Levitation or "containerless processing" can form pristine samples that can be probed in situ with the high-energy X-ray beam at Argonne's Advanced Photon Source. "This allows amorphization of the drug to be studied while it is being processed," said Rick Weber, who works on the project team at the synchrotron.

The acoustic levitator uses two small speakers to generate sound waves at frequencies slightly above the audible range - roughly 22 kilohertz. When the top and bottom speakers are precisely aligned, they create two sets of sound waves that perfectly interfere with each other, setting up a phenomenon known as a standing wave.

At certain points along a standing wave, known as nodes, there is no net transfer of energy at all. Because the acoustic pressure from the sound waves is sufficient to cancel the effect of gravity, light objects are able to levitate when placed at the nodes.

Although only small quantities of a drug can currently be "amorphized" using this technique, it remains a powerful analytical tool for understanding the conditions that make for the best amorphous preparation, Vaishnav explained.

Argonne researchers have already investigated more than a dozen different pharmaceuticals, and the laboratory's Technology Development & Commercialization Division is currently pursuing a patent for the method. Technology Development & Commercialization is also interested in partnering with the pharmaceutical industry to develop the technology further as well as to license it for commercial development.

After adapting the technology for drug research, the Argonne scientists teamed up with Professors Stephen Byrn and Lynne Taylor at the Department of Industrial and Physical Pharmacy at Purdue University and Jeffery Yarger of the Department of Chemistry and Biochemistry at Arizona State University. The group is now working on identifying which drugs the levitation instrumentation will impact most strongly.
-end-
Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy's Office of Science.

DOE's Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit science.energy.gov.

DOE/Argonne National Laboratory

Related Pharmaceuticals Articles from Brightsurf:

A plot twist in pharmaceuticals: Single nanoparticles could pave the way for medicines on demand
For the first time, a single, twisted nanoparticle has been accurately measured and characterised in a lab, taking scientists one vital step closer to a time when medicines will be produced and blended on a microscopic scale.

New pharmaceuticals: public research combines efficiency with contained costs
Is the basic research that goes into the development of new drugs more efficiently conducted by public-sector scientists, pharmaceutical firms, or independent private laboratories?

New STM technique points way to new and purer pharmaceuticals
A research project led by chemists at the University of Warwick first used ultrahigh resolution scanning tunnelling microscopy to see the exact location of atoms and bonds within a molecule, and then employed these incredibly precise images to determine the interactions that bond molecules to one another.

Study describes cocktail of pharmaceuticals in waters in Bangladesh
An analysis revealed that water samples held a cocktail of pharmaceuticals and other compounds, including antibiotics, antifungals, anticonvulsants, anesthetics, antihypertensive drugs, pesticides, flame retardants and more.

Treating wastewater with ozone could convert pharmaceuticals into toxic compounds
With water scarcity intensifying, wastewater treatment and reuse are gaining popularity.

Study calls for improved sanitation and the environmental management of pharmaceuticals
Failure to ensure the environmental sustainability of growing patient access to medicines in developing economies could increase the risk of adverse environmental impacts, according to new research led by the University of Plymouth.

Chemicals for pharmaceuticals could be made cheaper and greener by new catalysts
High value chemicals used to make pharmaceuticals could be made much cheaper and quicker thanks to a series of new catalysts made by scientists at the University of Warwick in collaboration with GoldenKeys High-Tech Co., Ltd. in China.

Soaking up pharmaceuticals and personal care products from water
Medications excreted in the urine or dumped into the toilet can end up in the water supply, just like lotions or cosmetics that wash off the body and go down the sink or shower drain.

New study finds river wildlife contain cocaine, pharmaceuticals and pesticides
For the first time, researchers at King's College London, in collaboration with the University of Suffolk, have found a diverse array of chemicals, including illicit drugs and pesticides in UK river wildlife.

Metal-free catalyst to convert aldehyde into ketone, a basic structure of pharmaceuticals
We succeeded in synthesizing a ketone, a basic structure of many pharmaceuticals, from an aldehyde and a carboxylic acid using N-heterocyclic carbene catalyst under mild conditions.

Read More: Pharmaceuticals News and Pharmaceuticals Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.